Inhibition of the Mevalonate Pathway Targets Neuroblastoma Stem Cells

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Pharmacology

Background:

• High-risk neuroblastoma is a challenging cancer with frequent recurrence and treatment resistance.
• Cancer stem cells are implicated as a key driver of neuroblastoma's aggressive nature.
• Mevalonate pathway inhibitors, including statins and bisphosphonates, have shown potential anticancer effects.

Purpose of the Study:

• To investigate the efficacy of mevalonate pathway inhibitors against high-risk neuroblastoma cancer stem cells.
• To assess the impact of these inhibitors on neuroblastoma spheroid formation and stemness characteristics.

Main Methods:

• Utilized spheroid-based assays with high-risk neuroblastoma cell lines (SH-SY5Y, SK-N-AS, SK-N-BE(2)-C).
• Treated cells with specific mevalonate pathway inhibitors: fluvastatin and zoledronate.

Main Results:

• Observed significant reductions in spheroid formation capability.
• Demonstrated decreased stem cell frequency and stemness properties in treated neuroblastoma cells.
• Fluzolmedronate and zoledronate treatments were effective against cancer stem cell populations.

Conclusions:

• Mevalonate pathway inhibitors effectively reduce neuroblastoma cancer stem cell function.
• The observed effects are linked to reductions in protein geranylgeranylation.
• These findings suggest a potential therapeutic strategy targeting cancer stem cells in neuroblastoma.